- Seal Sands Chemicals licenses biocompatible polymer technology based on Phosphorylcholine (PC) derivatives from Biocompatibles International.
- The agreement includes patent rights, process technology, applications, and trademarks associated with PC Technology™.
- Seal Sands has been producing these polymer materials for the eye care market to reduce eye irritation and improve comfort.
- The technology platform aims to expand into other health and personal care market segments.
License Agreement Details
Seal Sands Chemicals, part of Vertellus Specialties Inc., has signed a license agreement with Biocompatibles International to acquire biocompatible polymer technology based on Phosphorylcholine (PC) derivatives. The agreement encompasses patent rights, process technology, applications, and trademarks related to PC Technology™.
Manufacturing and Market Control
Neil McLoughlin, Vice President of the Health and Specialty Products division Europe, highlighted that Seal Sands has been producing these novel polymer materials at their UK site for several years. The agreement allows the company to leverage its manufacturing expertise and expanded capacity, gaining direct market control of these materials.
Applications in Eye Care
Seal Sands has primarily produced PC Technology™ materials for the eye care market, where they are used in contact lenses to inhibit protein deposition, thereby reducing eye irritation and improving comfort.
Future Expansion
Mike Driver, who will continue as Business Director under the newly formed Biomaterials business of Seal Sands, noted the robust opportunity pipeline. The company plans to expand and develop these opportunities by leveraging Vertellus' manufacturing and marketing strengths. The PC Technology™ platform, already a market leader in many medical applications, is well-positioned to grow into other health and personal care market segments.
